NOVARTIS AG | Sales 2024 * | 48.78B 45.63B 3,905B | Sales 2025 * | 50.62B 47.34B 4,052B | Capitalization | 200B 187B 15,982B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.37B 9.7B 830B | Net income 2025 * | 11.9B 11.12B 952B | EV / Sales 2024 * | 4.35 x |
| Net Debt 2024 * | 12.65B 11.83B 1,013B | Net Debt 2025 * | 11.18B 10.46B 895B | EV / Sales 2025 * | 4.17 x |
| P/E ratio 2024 * |
19.4
x | P/E ratio 2025 * |
16.7
x | Employees | 76,057 |
| Yield 2024 * |
3.69% | Yield 2025 * |
3.82% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 31/12/04 | |
| Director of Finance/CFO | 59 | 31/12/02 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 31/12/12 |
Simon Moroney
BRD | Director/Board Member | 65 | 27/02/20 |
| Chairman | 68 | 31/12/12 |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
